首頁 › 轉移性癌症 › 德克薩斯州 › Fort Worth
Fort Worth, TX 的 轉移性癌症 臨床試驗
7 項針對 轉移性癌症 的研究正在 Fort Worth（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
招募中1 期
- START Center for Clinical Research, Fort Worth
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
招募中1 期
- START Dallas Fort Worth, Fort Worth
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
招募中3 期
- Texas Oncology - DFW, Fort Worth
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
招募中1/2 期
- START Dallas Fort Worth, Fort Worth
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
招募中1/2 期
- University of Texas Southwestern Simmons Cancer Center - Fort Worth, Fort Worth
A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
招募中3 期
- Research Site, Fort Worth
A Study of IDP-001 in Advanced or Metastatic Solid Tumors
招募中1/2 期
- START Dallas Forth Worth, Fort Worth
其他城市的 轉移性癌症 試驗
- Houston, TX104 項研究
- New York City, NY93 項研究
- Nashville, TN70 項研究
- Boston, MA63 項研究
- Los Angeles, CA57 項研究
- St. Louis, MO54 項研究
- Arlington, VA53 項研究
- Philadelphia, PA46 項研究
- Chicago, IL45 項研究
- San Antonio, TX44 項研究
- Washington, DC43 項研究
- Dallas, TX42 項研究
Fort Worth 的其他研究
- 非小細胞肺癌18 項研究
- 卵巢癌17 項研究
- 子宮內膜癌12 項研究
- 乳癌12 項研究
- 癌症（所有類型）9 項研究
- 前列腺癌9 項研究
- 三陰性乳癌7 項研究
- 黃斑部病變7 項研究
- 潰瘍性結腸炎7 項研究
- 腎臟癌（腎細胞癌）7 項研究
- 心臟衰竭7 項研究
- 大腸直腸癌7 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。